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HORMESIS IN REGULATORY RISK ASSESSMENT - SCIENCE AND SCIENCE
POLICY
George Gray  Department of Environmental and Occupational Health, Center
for Risk Science and Public Health, George Washington University, School of
Public Health and Health Services
 This brief commentary will argue that whether hormesis is considered in regulatory
risk assessment is a matter less of science than of science policy. I will first discuss the dis-
tinction between science and science policy and their roles in regulatory risk assessment.
Then I will focus on factors that influence science policy, especially as it relates to the con-
duct of risk assessments to inform regulatory decisions, with a focus on the U.S.
Environmental Protection Agency (EPA). The key questions will then be how does horme-
sis interact with current concepts of science and science policy for risk assessment? Finally,
I look ahead to factors that may increase, or decrease, the likelihood of hormesis being
incorporated into regulatory risk assessment.
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SCIENCE POLICY
Science policy can be thought of as the bridge between specific acts
of science, whether experimental studies, measurements, observational
studies or modeling of processes, and making social decisions in the pol-
icy realm. For many health and environmental questions this bridging
function takes place through the risk assessment process. Essentially, sci-
ence policy is policy about how science will be used to inform decisions.
Science policy is necessary because no single scientific study is sufficient
to inform decisions and analytic choices must be made in the face of
uncertainty created by conflicting studies, alternative models and com-
peting theories.
The National Research Council (NRC) panel that first tackled feder-
al risk assessment practice also confronted the issue of science policy as
reflected in a later NRC report (NRC, 1994): “Risk assessors might be
faced with several scientifically plausible approaches (e.g., choosing the
most reliable dose-response model or extrapolation beyond the range of
observable effects) with no definitive basis for distinguishing among
them. The earlier Committee [NRC 1983 (The “Red Book”)] pointed out
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that selection of a particular approach under such circumstances involves
what it called a science-policy choice. Science policy choices are distinct
from the policy choices associated with ultimate decision-making...”
The regulatory risk assessment process, as currently practiced, often
has a goal of a single number characterization of risk like a Reference
Dose (RfD) or Cancer Slope Factor (CSF) meaning that science policy
decisions often have to be made in deciding which data to rely upon. Key
questions can include:
• Should toxicologic or epidemiologic study form the basis for an assess-
ment?
• Which study should be used?
• If using toxicology which species, which sex, which endpoint should be
the basis of the risk assessment?
In addition assessors confront questions about how to choose expo-
sure measures or dose metrics. If exposures are modeled, which model
should be used? How should the dose-response relationship be extrapo-
lated from exposures in toxicology or epidemiology studies to the levels
of concern? These are not simple questions and the choice made can be
significant. As a simple demonstration, using analysis from Evans et al.
(1994) and assuming 10,000.0000 people exposed to a background level
of 3.45 ppb of formaldehyde in air, 20 m3 air breathed per day and 70
years of exposure the choice of dose-response model leads to prediction
of excess cancers of 0 for a probit model, <1 for a multistage model, and
about 21,000 for a one-hit model. In the absence of compelling informa-
tion about the scientific appropriateness of one model or another, the
choice becomes a matter of science policy.
The way in which these science policy considerations are approached
varies from agency to agency in the Executive Branch of the US
Government in ways that do not depend on statute or legal authority
(Rosenthal et al., 1992; Rhomberg, 1997). Instead, science policy is often
reflective of the mission or culture of an agency and may be informed by
factors such as concern about safety, equity, or burden of proof. As a
quick example, consider liver tumors found in long-term bioassays of
mice. These are the most common tumors found in rodent cancer tests
(Gold et al., 1991). In general, the U.S. Food and Drug Administration
(FDA) downplays the relevance of these tumors to humans and numer-
ous pharmaceutical and over the counter drugs have been approved in
spite of increased rates of liver tumors in bioassays. EPA on the other
hand, virtually always takes findings of mouse liver tumors as relevant to
humans and, for example, many of the chemicals often found at
Superfund sites (EPA, 2010b) (often why the site is considered for
Superfund status) are regulated based on mouse liver tumors (e.g., EPA
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1991, 1995, 1996, 2010a). There is no statutory direction to EPA to rely
on liver tumors and FDA to discount them. There is no scientific infor-
mation known to FDA and not to EPA. Instead, each organization has
chosen a different science policy approach to dealing with a fundamen-
tal scientific uncertainty inherent in risk assessment.
For the US EPA science policy for risk assessment is often imple-
mented through guidance documents. These include guidance for risk
assessment of carcinogens, developmental toxicants and ecological stres-
sors1. These documents describe the Agency’s science policy framework
for EPA risk assessors and have a great influence on the way assessments
are carried out in state and local governments and the private sector.
It is clear that one of the factors guiding EPA science policy is a desire
to minimize the likelihood of underestimating risk when confronted by
scientific alternatives. For example, the Cancer Risk Assessment
Guidelines (EPA, 2005) make clear that “conservatism” is a goal guiding
science policy choices about dose-response evaluation – “It is the Agency’s
long-standing science policy position that use of the linear low-dose
extrapolation approach provides adequate public health conservatism in
the absence of chemical-specific data indicating differential early-life sen-
sitivity or when the mode of action is not mutagenic.” The notion of “pub-
lic health conservatism” clearly informs both Agency science policy and
its implementation. The development of rules to deal with science choic-
es under uncertainty is important but of potentially greater significance
is how those rules are used (e.g., the determination that a chemical’s
mode of action is mutagenic in the example above).
SCIENCE AND HORMESIS
There is an extensive literature on hormetic responses in a wide
range of biological systems and settings (for reviews see Calabrese and
Baldwin, 2001; Calabrese and Blain, 2005). Indeed EPA has funded
research looking for, and finding, evidence of hormetic responses2. The
Agency’s 2003 edition of the Annual Toxicology and Risk Assessment
Conference devoted a major session to “Hormesis in Human Health
and Ecological Risk Assessment.” Agency science advisors have encour-
aged EPA to look more closely at hormetic effects, although the advice
has been controversial even within the same science panel3. Clearly EPA
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At the same time, there is dissent in the scientific community. Some
focuses on the science of hormesis and some on the policy implications of
including hormetic effects in risk assessment procedures. As an example
of the former, Mushak (2007) has written about his concerns that horme-
sis is ill defined, its prevalence unknowable and its biological basis unclear.
He concludes in his paper that “Definition, characterization, occurrence,
and mechanistic rationale for hormesis will remain speculative, absent rig-
orous studies done specifically for hormesis testing. Any role for hormesis
in current risk assessment and regulatory policies for toxics remains to be
determined.” Others have raised both scientific and policy concerns.
Thayer et al. (2005) review areas in which the theory and evidence for
hormesis is, in their view, lacking. These include questions of variability in
response and mechanistic underpinnings. They conclude that considering
hormesis in risk assessment would detract from its “public health protec-
tive” policy position. The sum up their view thusly “The claims and pro-
jections of health benefits from exposures to environmental toxicants and
carcinogens are based on untested assumptions and disregard numerous well-
established scientific principles that underpin a public health-protective approach to
regulating exposure to toxic substances” (emphasis added).
SCIENCE POLICY - WHERE ARE WE TODAY?
We have seen that regulatory risk assessors must be quite aware of
hormesis, both the evidence for the phenomenon and the concerns, both
scientific and policy oriented, that have been raised. What science policy
positions have been taken on hormesis? The answer is none – except by
omission. At this point there is no mention of hormesis in any EPA risk
assessment guidance document including those for Cancer Risk
Assessment (EPA 2005), Developmental Toxicity Risk Assessment (EPA
1991) and Neurotoxicity Risk Assessment (EPA 1998). Hormesis is not
Hormesis Science and Science Policy
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3. EPA’s SAB was split in its view on hormesis when looking at dioxins. The report reads
(page 79) “The Committee urges EPA to examine fundamental principles of receptor theory,
and the evidence from the epidemiological and toxicological data bases in the low exposure
ranges for their consistency with its assumption of a linear, non-threshold carcinogenic risk. In
addition, the Committee (with several exceptions) believe that the Agency should at least con-
sider the suggestion from the public regarding evidence for reduced cancer risks associated
with very low levels of exposure. Although such a concept seems to be counterintuitive, there
is a body of literature (albeit debatable, and both pro and con) on the concept of hormesis and
ionizing radiations biological effects; this concept was not discussed during the review meeting
but is mentioned as an possible area of future investigation.” But the footnote on the same page
says “Several members of the committee believe that the evidence of “hormesis” for dioxin-like
compounds is not statistically or experimentally significant at this time, and that until more
solid evidence is obtained this issue is irrelevant. These members also contend that the
putatitve “hormesis” effects are occurring at the levels of exposure at which the developmental
and immunological alterations are seen.” Re-evaluating Dioxin: Science Advisory Board’s Review of
EPA’s Reassessment of Dioxin and Dioxin-like Compounds. EPA SABEC950121F
4
Dose-Response: An International Journal, Vol. 9 [2014], Iss. 2, Art. 2
https://scholarworks.umass.edu/dose_response/vol9/iss2/2
explicitly excluded from consideration but no direction is given on how
to incorporate it into an assessment. Without specific science policy guid-
ance on how to make choices about when and how to consider hormesis
it is highly unlikely to be incorporated into EPA assessments.
I believe hormesis is “shut out” of current risk assessment procedures
for reasons of both science and science policy. The science issues may be
amenable to research and investigation but science policy views may have
greater influence. Several of the science questions raised by Mushak
(2007) and Thayer et al. (2005) are appropriate and can be investigated
experimentally and observationally. Understanding interspecies and
intraspecies variability in hormetic responses, especially quantitatively, is
clearly an important need to inform any use in risk assessment.
Epidemiologic evidence of hormesis would likely be quite persuasive.
The science policy issues, however, are driven more by a regulatory
agency’s perspective on decision making under uncertainty, its view of the
best way to carry out its mission, and the history and culture that influ-
ence specific choices. This is perhaps best exemplified by the EPA’s
notion of “health protective” or “public health conservative” science pol-
icy choices in the carcinogen risk assessment process (EPA 2005). As long
as the consideration of hormesis is seen as not health protective or, in the
words of Thayer et al. (2005), having the implication that it would “allow
higher exposures to toxic and carcinogenic agents” we are unlikely to see
changes in the science policy underlying regulatory risk assessment.
In addition, there are no widely accepted examples in which ignoring
a hormetic response has resulted in public health harm although it is
clearly theoretically possible that ignoring a true hormetic effect would
actually contravene the notion of public health conservatism underlying
much of risk assessment science policy4.
WHAT MIGHT CHANGE THINGS?
In my view, hormesis will not be incorporated into regulatory risk
assessment science policy until there is demand from decision makers.
The science policy culture of regulatory risk assessment suggests that the
G. Gray
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4. A cogent description of this phenomenon can be found in Sunstein, C.R. (2003)
Beyond the Precautionary Principle. University of Pennsylvania Law Review 151: 1003-1058 “Some
evidence suggests that many toxic agents that are harmful at high levels are actually beneficial
at low levels. Thus, hormesis is a dose-response relationship in which low doses stimulate desir-
able effects and high doses inhibit them. When hormesis is involved, use of a linear dose-
response curve, with out safe thresholds, will actually cause mortality and morbidity effects.
Which default approach to the dose-response curve is precautionary? To raise this question is
not to take any stand on whether some, many, or all toxic agents are beneficial or instead harm-
ful at very low doses; it is only to say that the simultaneous possibility of benefits at low levels
and of harms at low levels makes the precautionary principle paralyzing.” In this case precau-
tion can be taken as a synonym for “public health conservative”
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perception that considering hormesis is not public health protective
means it is unlikely to be advocated by the risk assessors.
If the use of risk assessment begins to evolve from the standard setting
uses of the past to the more decision focused approaches advocated in
the 2009 National Research Council Report Science and Decisions (NRC
2009), risk managers may begin to request assessors to consider hormet-
ic effects. As envisioned by the NRC risk assessments will support weigh-
ing alternative risk management options. The risk assessment will be tai-
lored in complexity to inform the specific choices that have to be made.
Inherent in this way of thinking is the realization that there are public
health risks on both sides of a choice (Graham and Wiener, 1995). In this
case, decision makers will want (and need) best estimates of risk not
“health protective” estimates with unknown (and often different levels of)
conservatism (Gray, 1996; Ohanian et al., 1997; Gray and Hammitt, 2000).
Best estimates of risk will involve the consideration of all relevant scien-
tific information (including hormesis), careful characterization of dose-
response including the potential for non-linear, threshold and non-
monotonic forms, and description of variability in exposure.
Unless this sort of change in the basic approach to risk assessment
and management occurs the only thing I foresee forcing a reconsidera-
tion of hormesis in regulatory risk assessment is a clear public health case
that not considering low dose non-monotonicity is a threat to public
health. I don’t see any examples of this on the horizon.
SUMMARY
Regulatory risk assessments are clearly a mix of science and science
policy. Making consistent and reproducible decisions about which stud-
ies, data, models and approaches to use in assessments is the traditional
argument for science policy guidelines. The content of these policies and
guidelines is informed by agency history, culture and view of their mis-
sion. Different agencies have different science policy approaches to the
same risk assessment issues.
There are still science questions regarding hormesis and the way it
should inform risk assessment. These include a lack of understanding of
the biological basis of hormesis, lack of clarity about its definition and
questions about population variability in both hormetic and adverse
effects of exposures. It is my belief that future research can, and will,
begin to resolve many of these issues.
However, acceptance of hormesis in science policy choices is only
partly informed by advances in science. Because science policy seeks to
provide guidance in the face of scientific uncertainty, and there will
always be some level of uncertainty in many aspects of risk assessment, an
agency’s view of its mission, its history and its culture will play a large role
in whether hormesis will be considered in risk assessment. Until there is
Hormesis Science and Science Policy
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demand from risk managers for best estimates of risk, I believe hormesis
will continue to be excluded from risk assessment because of the belief
that its inclusion would not be “health protective.”
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